Want to see IXHL full AI Analyst Report?
IXHL Stock Chart & Stats
$0.39
-$0.11(-5.37%)
At close: 4:00 PM EST
$0.39
-$0.11(-5.37%)
Day’s Range― - ―
52-Week Range$2.49 - $49.80
Previous CloseN/A
Volume10.98K
Average Volume (3M)303.73K
Market Cap
$40.32M
Enterprise Value-$30.07M
Total Cash (Recent Filing)$68.90M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta3.72
Next Earnings
Sep 02, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding11,964,554
10 Day Avg. Volume284,123
30 Day Avg. Volume303,725
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.75
Enterprise Value/Revenue-451.35
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.66
Forecast
1Y Price Target
$18.00Price Target Upside4515.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$40.00M
Bulls Say, Bears Say
Bulls Say
US Patent For IHL-42XA granted U.S. patent to 2040 provides durable market exclusivity for the lead OSA candidate, strengthening bargaining power for partnerships or licensing. Long-dated IP reduces competitor entry risk, increases asset commercial value, and supports long-term strategic optionality for the program.
Material Non-dilutive FundingSignificant non-dilutive refunds bolster runway without equity issuance, improving financial flexibility to advance clinical programs. This reduces near-term dilution risk, supports R&D continuity and share buybacks, and meaningfully enhances the firm's ability to fund mid-stage trials.
Advancing Mid-stage Clinical ProgramCommencing a well-resourced dose-optimization study demonstrates operational execution and de-risks the Phase III pathway. Refining dosing and global site setup improves probability of successful later-stage trials, increases partner interest, and enhances the program's long-term commercialization prospects.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow drains resources and makes the company dependent on external funding or non-dilutive credits. Continued cash burn constrains strategic optionality, may force reprioritization of programs, and raises financing and dilution risk over the medium term.
Heavy Losses And Minimal RevenueVery low revenues and large net losses indicate the business is not yet commercially viable. Persistent negative margins mean the balance sheet must fund operations until successful product commercialization, elongating the path to self-sufficiency and increasing execution pressure.
Clinical-stage, Binary Development RiskA reliance on clinical progress means company value hinges on trial and regulatory outcomes, which are binary and time-consuming. Limited commercial revenue streams and a small operational team raise execution and scale risks if multiple programs must be advanced concurrently.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.49 and its highest was $49.80 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $40.32M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Sep 02, 2026 which is in 52 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Mar 02, 2026. The company reported -$0.6 earnings per share for the quarter, the consensus estimate of -$0.6 by $0.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Undervalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate is -0.14.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 11,964,554 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.6 in its last earnings report, expectations of -$0.6. Following the earnings report the stock price went down -9.906%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (4515.38% Upside)
$18.00 (4515.38% Upside)
Blogger Sentiment
Bullish
IXHL Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.77%
12-Months-Change
Fundamentals
Return on Equity
-122.57%
Trailing 12-Months
Asset Growth
395.67%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
IXHL Stock 12 Month Forecast
Average Price Target
$18.00
▲(4515.38% Upside)
Technical Analysis
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
Currently, No data available
---